Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

GeneDx Holdings Q3 2026 Results: Net Loss of $12.3M, Loss Widens

For the nine months ended September 30, 2026, GeneDx reported total revenue of $339.8 million, an 11% increase year-over-year, though net loss widened significantly to $93.4 million due to a $31.3 million impairment loss and increased SG&A expenses. The company strengthened its balance sheet by securing $146.0 million in long-term debt proceeds while repaying its previous Perceptive debt facility.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue123.1116.7
Gross profit86.184.5
Profit before tax-12.3-7.4
Net income-12.3-7.6
EPS (diluted, $ a share)$-0.41$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+5.4%
Gross margin69.9%
Operating margin-8.5%
Source

10-Q filed with the SEC, NASDAQ: WGS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

GeneDx Holdings Corp.: key numbers

Share price
$51.02Close, Nov 16
Market cap
$1.53B
Shares outstanding
29.97MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Health ServicesSIC 8000

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from GeneDx Holdings Corp.

All →
4:11 PM ET 8-K
Financial Results

GeneDx Holdings Financial Results

GeneDx reported Q3 2026 revenue of $123.1 million, driven by 25% year-over-year growth in exome and genome test volume. The company achieved adjusted net income of $8.6 million and expanded its adjusted gross margin to 72%. Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.

Term
Q3 2026

“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”

Katherine Stueland, CEO of GeneDx
4:43 PM ET Form 4
Insider Selling

GeneDx Holdings CEO Katherine Stueland Sells $1.03M of Stock

Katherine Stueland, CEO, sold 10,501 shares of GeneDx Holdings Corp. at $94.26 to $99.00 a share (average $97.61) in 5 transactions, worth $1.03M in total on Sep 16, 2026. Shares held after the trade: 115,476 (-2.6%).

Value
$1.03M
Shares
10,501
Average price
$97.61
Role
CEO
Holding change
-2.6%
Trade date
Sep 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.